growth hormone therapy for prader–willi syndrome: challenges and solutions

Clicks: 256
ID: 149764
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #20 of 91 articles by views in liver transplantation : official publication of the american association for the study of liver diseases and the international liver transplantation society

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Graziano Grugni,1,2 Alessandro Sartorio,1,2 Antonino Crinò3 1Division of Auxology, 2Experimental Laboratory for Auxo-endocrinological Research, San Giuseppe Hospital, Istituto Auxologico Italiano, Verbania, 3Autoimmune Endocrine Diseases Unit, Bambino Gesù Children’s Hospital, Rome, Italy Abstract: Prader–Willi syndrome (PWS) is characterized by a dysregulation of growth hormone (GH)/insulin-like growth factor I axis, as the consequence of a complex hypothalamic involvement. PWS’ clinical picture seems to resemble the classic non-PWS GH deficiency (GHD), including short stature, excessive body fat, decreased muscle mass, and impaired quality of life. GH therapy is able to ameliorate the phenotypic appearance of the syndrome, as well as to improve body composition, physical strength, and cognitive level. In this regard, however, some pathophysiologic and clinical questions still remain, representing a challenge to give the most appropriate care to PWS patients. Data about the prevalence of GHD in PWS children are not unequivocal, ranging from 40% to 100%. In this context, to establish whether the presence (or not) of GHD may have a different effect on clinical course during GH therapy may be helpful. In addition, the comparison of GH effects in PWS children diagnosed as small for gestational age with those obtained in subjects born appropriate for gestational age is of potential interest for future trials. Emerging information seems to demonstrate the maintenance of beneficial effects of GH therapy in PWS subjects after adolescent years. Thus, GH retesting after achievement of final height should be taken into consideration for all PWS patients. However, it is noteworthy that GH administration exerts positive effects both in PWS adults with and without GHD. Another critical issue is to clarify whether the genotype–phenotype correlations may be relevant to specific outcome measures related to GH therapy. Moreover, progress of our understanding of the role of GH replacement and concomitant therapies on bone characteristics of PWS is required. Finally, a long-term surveillance of benefits and risks of GH therapy is strongly recommended for PWS population, since most of the current studies are uncontrolled and of short duration. Keywords: PWS, GH deficiency, GH therapy, transition phase
Reference Key
g2016therapeuticsgrowth Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Grugni G;Sartorio A;Crinò A
Journal liver transplantation : official publication of the american association for the study of liver diseases and the international liver transplantation society
Year 2016
DOI
DOI not found
URL
https://www.dovepress.com/growth-hormone-therapy-for-praderndashwilli-syndrome-challenges-and-so-peer-reviewed-article-TCRM
Keywords
prader-willi syndrome gh deficiency transition phasemedicine (general)

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.